Esperion TherapeuticsESPR
Market Cap: $318M
About: Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Employees: 240
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
102% more call options, than puts
Call options by funds: $7.09M | Put options by funds: $3.5M
88% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 26
81% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 31
17% more funds holding
Funds holding: 149 [Q1] → 174 (+25) [Q2]
3.59% more ownership
Funds ownership: 68.59% [Q1] → 72.18% (+3.59%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
11% less capital invested
Capital invested by funds: $340M [Q1] → $304M (-$36.5M) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Needham Serge Belanger 50% 1-year accuracy 58 / 115 met price target | 257%upside $6 | Buy Maintained | 13 Aug 2024 |
HC Wainwright & Co. Joseph Pantginis 38% 1-year accuracy 103 / 273 met price target | 852%upside $16 | Buy Reiterated | 12 Aug 2024 |
Needham Serge Belanger 50% 1-year accuracy 58 / 115 met price target | 376%upside $8 | Buy Reiterated | 28 Jun 2024 |
HC Wainwright & Co. Joseph Pantginis 38% 1-year accuracy 103 / 273 met price target | 852%upside $16 | Buy Reiterated | 28 Jun 2024 |
Financial journalist opinion
Based on 3 articles about ESPR published over the past 30 days